The Manufacturers Life Insurance Company Invests $75,000 in Atossa Therapeutics, Inc. (NASDAQ:ATOS)

The Manufacturers Life Insurance Company purchased a new stake in Atossa Therapeutics, Inc. (NASDAQ:ATOS) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 49,113 shares of the company’s stock, valued at approximately $75,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. XTX Topco Ltd purchased a new stake in shares of Atossa Therapeutics during the 2nd quarter valued at approximately $29,000. Intech Investment Management LLC purchased a new stake in Atossa Therapeutics in the third quarter valued at $29,000. SG Americas Securities LLC grew its holdings in shares of Atossa Therapeutics by 254.3% during the 3rd quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock worth $64,000 after purchasing an additional 30,037 shares during the period. Rhumbline Advisers acquired a new stake in shares of Atossa Therapeutics during the 2nd quarter worth about $161,000. Finally, Bank of New York Mellon Corp raised its holdings in Atossa Therapeutics by 3,160.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock valued at $490,000 after buying an additional 399,041 shares during the period. Institutional investors and hedge funds own 12.74% of the company’s stock.

Atossa Therapeutics Trading Down 2.8 %

Shares of NASDAQ ATOS opened at $1.04 on Wednesday. The stock has a market cap of $130.83 million, a P/E ratio of -4.73 and a beta of 1.21. The business’s fifty day simple moving average is $1.34 and its 200-day simple moving average is $1.32. Atossa Therapeutics, Inc. has a 12-month low of $0.70 and a 12-month high of $2.31.

Analysts Set New Price Targets

ATOS has been the topic of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Atossa Therapeutics in a research note on Thursday, December 12th. Ascendiant Capital Markets raised their price target on Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Finally, StockNews.com lowered Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, November 18th.

Atossa Therapeutics Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.